Kyotorphin acetate is an endogenous peptide with analgesia activity and can be used as a biomarker of Alzheimer disease.

The release of immunoreactive Met-enkephalin (I-ME) from the rat striatum was studied in vitro using a batch technique. A basal release of the order of 2-3% of total I-ME tissue content per 10 min was found. Kyotorphin produced dose-dependent I-ME release, with 0.5 mM maximal concentration causing 2-3-fold stimulation of release. This release was calcium-dependent. In concentrations up to 1 mM Kyotorphin did not change the basal release of [3H]noradrenaline, [3H]GABA, [3H]D-aspartate and immunoreactive beta-endorphin from various brain structures.

Kyotorphin produced a naloxone-reversible potent analgesic effect, yet no inhibitory effect on electrically induced contractions of longitudinal muscle of the guinea pig ileum.

T20172L

C17H27N5O6

397.43

Kyotorphin acetate

DMSO:65 mg/ml (163.55 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years